Light chain analysis increased and Hearing loss

Summary:

Hearing loss is found among people with Light chain analysis increased, especially for people who are female, 50-59 old.

The study analyzes which people have Hearing loss with Light chain analysis increased. It is created by eHealthMe based on reports of 12 people who have Light chain analysis increased from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Light chain analysis increased?

Light chain analysis increased is found to be associated with 197 drugs and 149 conditions by eHealthMe. Check the latest studies of Light chain analysis increased.

What is Hearing loss?

Hearing loss is found to be associated with 1,358 drugs and 2,386 conditions by eHealthMe. Check the latest studies of Hearing loss.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 11, 2026

12 people who have Light Chain Analysis Increased and Hearing Loss are studied.

Would you have Hearing loss when you have Light chain analysis increased?

Gender of people who have Light Chain Analysis Increased and experienced Hearing Loss *:

female: 100 %
male: 0.0 %

Age of people who have Light Chain Analysis Increased and experienced Hearing Loss *:

Common co-existing conditions for these people *:

Multiple Myeloma (cancer of the plasma cells): 12 people, 100.00%

Common drugs taken by these people *:

Zoloft: 12 people, 100.00%
Coumadin: 12 people, 100.00%
Zofran: 12 people, 100.00%
Flutamide: 12 people, 100.00%
Fludrocortisone Acetate: 12 people, 100.00%
Florinef: 12 people, 100.00%
Ditropan Xl: 12 people, 100.00%
Decadron: 12 people, 100.00%
Cephalexin: 12 people, 100.00%
Lotrel: 12 people, 100.00%

Common symptoms for these people *:

Weight Decreased: 12 people, 100.00%
Weakness: 12 people, 100.00%
Gait Disturbance: 12 people, 100.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 12 people, 100.00%
Gingival Disorder (gum disease): 12 people, 100.00%
Hypoaesthesia (reduced sense of touch or sensation): 12 people, 100.00%
Indigestion: 12 people, 100.00%
Infection: 12 people, 100.00%
Irritable Bowel Syndrome: 12 people, 100.00%
Night Sweats (sweating in night): 12 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .

Related studies:

Treatments, associated drugs and conditions:

Light chain analysis increased (1,086 reports)
Hearing loss (30,352 reports)

All the drugs that are associated with Hearing loss:

Hearing loss (1,358 drugs)

All the conditions that are associated with Hearing loss:

Hearing loss (2,386 conditions)

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Hearing loss and Light chain analysis increased, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.